First patient treated with LC Bead LUMI radiopaque embolic bead supported by Philips live image guidance

04/02/2016

London, UK and Amsterdam, the Netherlands - BTG plc (LSE: BTG), a global specialist healthcare company, and Royal Philips (NYSE: PHG; AEX: PHIA), a global leader in image-guided therapy, announced today a significant milestone in their collaboration with the treatment of the first liver cancer patient with LC Bead LUMI in conjunction with Philips live image guidance, targeting a hypervascular tumor with the goal to block blood flow to achieve tumor necrosis.

Liver cancer is the second leading cause of cancer deaths in the world [1], and one of the most challenging to treat. Each year, more than 700,000 patients worldwide are diagnosed with liver cancer [2]. Interventional embolization is an option for some patients with tumors that cannot be removed by surgery.

The first patient treated signals the next stage in commercializing next generation embolic beads, which can be visualized during interventional procedures, allowing enhanced visualization to evaluate completeness of tumor treatment. As a result of the collaboration between BTG and Philips, for the first time doctors will be able to see rather than assume the location of the LC Bead LUMI , in order to deliver their treatment with more confidence when treating liver cancer.

The aim with this new radiopaque embolic bead and visualization technology is to provide clinicians like me the ability to make real-time adjustments while conducting the embolization procedure, so that we can optimize patients treatment and hopefully improve targeting accuracy, said Bradford Wood, M.D., Director of the NIH Center for Interventional Oncology [3] and Chief of Interventional Radiology. It is reassuring for the clinician and the patient to know that the treatment was delivered exactly where it was aimed, and where it was needed. Treating the first patient using LC Bead LUMI in combination with dedicated Philips 2D X-ray and 3D CBCT image guidance is a milestone in our public-private partnership with both of our industry research partners. The imaging of the beads during this first procedure was exquisite and provided valuable information.

By enabling visualization of beads during an embolization procedure, LC Bead LUMI will help embolization technology achieve its full potential. LC Bead LUMI has been developed with revolutionary radiopacity technology in collaboration with Philips that enables real-time visualization of bead location during embolization. LC Bead LUMI , supported by Philips live image guidance, has the potential to offer interventional radiologists more control, allowing enhanced visualization to evaluate the completeness of tumor treatment and end-point determination.

BTG continues to advance its leadership in Interventional Medicine by actively listening to our customers and providing creative solutions to meet their clinical needs, said Peter Pattison, Interventional Oncology General Manager, BTG. Several years ago, we began scientific collaboration with Philips to evaluate the benefits of better image-guided therapy and this venture resulted in the ability to calibrate Philips imaging software to LC Bead LUMI . The clinical impact of the BTG-Philips collaboration is now helping interventional radiologists and multi-disciplinary teams make enhanced treatment decisions for patients with liver cancer.

Minimally-invasive therapy procedures provide key benefits for healthcare systems and patients, and intelligent image guidance is an essential part of these procedures, said Ronald Tabaksblat, Business Leader Image Guided Therapy Systems at Philips. We aim to continuously improve Image Guided Therapy and our collaboration with BTG to provide enhanced visibility and guidance during interventional embolization procedures is another important milestone in this exciting journey to help deliver excellent treatment and enhanced patient care.

LC Bead LUMI was cleared for clinical use in the US in December 2015 after extensive laboratory testing based on the clinical foundation of its predicate device, LC Bead .

BTG and Philips will showcase their advancements in interventional oncology at the upcoming symposium on Clinical Interventional Oncology (CIO), taking place on February 6 and 7, 2016, in Hollywood, Florida.

For information on BTG, visit http://www.btg-im.com, and to learn more about Philips integrated solutions for diagnostics and therapeutic oncology, please visit http://www.philips.com/io.

[1]. World Health Organization (WHO). Cancer factsheet. Available at: http://www.who.int/mediacentre/factsheets/fs297/en/. Last accessed January 25, 2016.

[2]. American Cancer Society. What are the key statistics about liver cancer?. Available at: http://www.cancer.org/cancer/livercancer/detailedguide/liver-cancer-what-is-key-statistics. Last accessed January 25, 2016.

[3]. NIH does not endorse or recommend any commercial products, processes, or services. The views and opinions of authors expressed here do not necessarily state or reflect those of the US Government or the NIH, and they may not be used for advertising or product endorsement purposes.

LINK:	http://www.newscenter.philips.com/gb_en/standard/news/press/2016/20160...
	See more stories from philips

First patient treated with LC Bead LUMI radiopaque embolic bead supported by Philips live image guidance

More from Philips

14/12/2017

09/12/2017

09/12/2017

25/11/2017

25/11/2017

25/11/2017

24/10/2017

04/10/2017

18/09/2017

05/09/2017

14/08/2017

08/07/2017

06/07/2017

04/07/2017

15/06/2017

15/06/2017

15/06/2017

15/06/2017

08/04/2016

06/04/2016

07/03/2016

03/03/2016

03/03/2016

01/03/2016

25/02/2016

25/02/2016

23/02/2016

23/02/2016

23/02/2016

23/02/2016

04/02/2016

01/02/2016

26/01/2016

07/01/2016

06/01/2016

30/11/2015

18/11/2015

18/11/2015

17/11/2015

13/11/2015

10/11/2015

29/10/2015

26/10/2015

20/10/2015

15/10/2015

13/10/2015

13/10/2015

09/10/2015

02/10/2015

15/09/2015